BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn [Yahoo! Finance]
Brainstorm Cell Therapeutics Inc. (BCLI)
Last brainstorm cell therapeutics inc. earnings: 11/14 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.brainstorm-cell.com
Company Research
Source: Yahoo! Finance
NEW YORK April 16, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the promotion of Dr. Bob Dagher to Executive Vice President and Chief Medical Officer. In addition, after four years of maintaining top executive roles, Dr. Stacy Lindborg stepping down from the role of Co-CEO and will remain with BrainStorm as a member of its Board of Directors. These strategic management changes are being made as the Company prepares to embark on a registrational Phase 3b trial for NurOwn ® , its investigational cell therapy treatment for amyotrophic lateral sclerosis (ALS). Dr. Dagher has served as our Chief Development Officer since July 2023 . In his new role as Executive Vice President and Chief Medical Officer, Dr. Dagher's responsibilities will include overseeing the planned Phase 3b registration trial of NurOwn. The Company recently announced that it has reached agreeme
Show less
Read more
Impact Snapshot
Event Time:
BCLI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCLI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCLI alerts
High impacting Brainstorm Cell Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BCLI
News
- BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwnPR Newswire
- BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule [Yahoo! Finance]Yahoo! Finance
- BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value RulePR Newswire
- BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS [Yahoo! Finance]Yahoo! Finance
- BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALSPR Newswire
BCLI
Earnings
- 11/14/23 - Beat
BCLI
Sec Filings
- 4/25/24 - Form 4
- 4/22/24 - Form 3
- 4/19/24 - Form 4
- BCLI's page on the SEC website